Recent research from Sanofi highlights the significant impact of Type 1 Diabetes on those living with the conditionThe song, "Rise Up," shares their experiences of living with the condition ...

Something encouraging is on display throughout Gasoline Alley this May – new names and colors featured on an array cars with ...

Sanofi and Vietnam Vaccine JSC, or VNVC, on Tuesday launched a vaccine manufacturing facility in Vietnam, aimed at producing ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants ...

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Qualifyze, already the global leader in third-party audit services for the pharmaceutical industry, announces the launch of ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

Sanofi estimates that the annual cost for a typical patient will be around $280,000 per year before discounts or rebates, in line with other drugs used to treat rare, chronic diseases.

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...